NextCure Inc. provided an update on its ongoing clinical programs in its latest corporate presentation. The company reported progress on two differentiated antibody-drug conjugate $(ADC)$ programs that are currently in Phase 1 trials. These programs, LNCB74 targeting CDH6 with a TOPO payload and another targeting B7-H4 with an MMAE payload, are being developed in collaboration with Simcere Zaiming. NextCure anticipates proof-of-concept (POC) data for both ADCs in the first half of 2026. The presentation also provided an overview of research and development milestones and outlined the company's ongoing efforts in the development of targeted therapies for cancer. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief on October 16, 2025, and is solely responsible for the information contained therein.